## **Emanuele Perrone**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2844278/publications.pdf

Version: 2024-02-01

45 papers 836 citations

430874 18 h-index 28 g-index

45 all docs 45 docs citations

45 times ranked 989 citing authors

#	Article	IF	CITATIONS
1	The Senhanceâ,,¢ surgical robotic system ("Senhanceâ€) for total hysterectomy in obese patients: a pilot study. Journal of Robotic Surgery, 2018, 12, 229-234.	1.8	60
2	Laparoscopic vs transvaginal cuff closure after total laparoscopic hysterectomy: a randomized trial by the Italian Society of Gynecologic Endoscopy. American Journal of Obstetrics and Gynecology, 2018, 218, 500.e1-500.e13.	1.3	58
3	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22730-22736.	7.1	52
4	Laparoscopic, minilaparoscopic, single-port and percutaneous hysterectomy: Comparison of perioperative outcomes of minimally invasive approaches in gynecologic surgery. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 216, 125-129.	1.1	51
5	The surgical outcome of intracapsular cesarean myomectomy. A match control study. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 66-71.	1.5	45
6	Single-Institution Propensity-Matched Study to Evaluate the Psychological Effect of Minimally Invasive Interval Debulking Surgery Versus Standard Laparotomic Treatment: From Body to Mind and Back. Journal of Minimally Invasive Gynecology, 2018, 25, 816-822.	0.6	45
7	Bladeless Direct Optical Trocar Insertion in Laparoscopic Procedures on the Obese Patient. Journal of the Society of Laparoendoscopic Surgeons, 2013, 17, 521-528.	1.1	38
8	Total Laparoscopic (S-LPS) versus TELELAP ALF-X Robotic-Assisted Hysterectomy: A Case-Control Study. Journal of Minimally Invasive Gynecology, 2016, 23, 933-938.	0.6	37
9	Technological innovation and personalized surgical treatment for early-stage endometrial cancer patients: A prospective multicenter Italian experience to evaluate the novel percutaneous approach. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 234, 218-222.	1.1	33
10	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget, 2020, 11, 560-570.	1.8	32
11	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports, 2020, 10, 973.	3.3	31
12	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers in Oncology, 2020, 10, 118.	2.8	30
13	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology, 2019, 155, 144-150.	1.4	28
14	Needleoscopic Conservative Staging of Borderline Ovarian Tumor. Journal of Minimally Invasive Gynecology, 2017, 24, 529-530.	0.6	26
15	Sonographic markers for early diagnosis of fetal malformations. World Journal of Radiology, 2013, 5, 356.	1.1	25
16	3Âmm Senhance robotic hysterectomy: a step towards future perspectives. Journal of Robotic Surgery, 2018, 12, 575-577.	1.8	24
17	Role of blue dye for sentinel lymph node detection in early endometrial cancer. Gynecological Surgery, 2017, 14, 23.	0.9	21
18	Feasibility and perioperative outcomes of percutaneous-assisted laparoscopic hysterectomy: A multicentric Italian experience. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 245, 181-185.	1.1	21

#	Article	IF	CITATIONS
19	Sacituzumab govitecan, an antibodyâ€drug conjugate targeting trophoblast cellâ€surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas inÂvitro and inÂvivo. Molecular Oncology, 2020, 14, 645-656.	4.6	20
20	Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study. Journal of Gynecologic Oncology, 2021, 32, e45.	2.2	20
21	InÂvitro and inÂvivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology, 2020, 156, 430-438.	1.4	18
22	Sexual Function following Laparoscopic versus Transvaginal Closure of the Vaginal Vault after Laparoscopic Hysterectomy: Secondary Analysis of a Randomized Trial by the Italian Society of Gynecological Endoscopy Using a Validated Questionnaire. Journal of Minimally Invasive Gynecology, 2020, 27, 186-194.	0.6	15
23	Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. Journal of Experimental and Clinical Cancer Research, 2022, 41, 50.	8.6	15
24	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology, 2019, 153, 158-164.	1.4	13
25	A Multicentric Randomized Trial to Evaluate the ROle of Uterine MANipulator on Laparoscopic/Robotic HYsterectomy for the Treatment of Early-Stage Endometrial Cancer: The ROMANHY Trial. Frontiers in Oncology, 2021, 11, 720894.	2.8	11
26	The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. Gynecologic Oncology, 2022, 165, 585-593.	1.4	10
27	Percutaneous-assisted vs mini-laparoscopic hysterectomy: comparison of ultra-minimally invasive approaches. Updates in Surgery, 2020, 73, 2347-2354.	2.0	9
28	Automatic Evaluation of Progression Angle and Fetal Head Station through Intrapartum Echographic Monitoring. Computational and Mathematical Methods in Medicine, 2013, 2013, 1-8.	1.3	8
29	Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study. International Journal of Gynecological Cancer, 2017, 27, 1200-1205.	2.5	8
30	Robotic video endoscopic inguinal lymphadenectomy (R-VEIL) for vulvar cancer with sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology. Gynecologic Oncology, 2018, 150, 203-204.	1.4	8
31	Reply. Journal of Minimally Invasive Gynecology, 2017, 24, 683-684.	0.6	5
32	Laparoscopic Pelvic Exenteration With Radical Vaginectomy Using 3-Dimensional Vision and Multifunction Instrument. International Journal of Gynecological Cancer, 2018, 28, 1805-1806.	2.5	5
33	Percutaneous-Assisted versus Laparoscopic Hysterectomy: A Prospective Comparison. Gynecologic and Obstetric Investigation, 2020, 85, 318-326.	1.6	5
34	Treatment of gynecological disease in obese patient: which role for telelap ALF-X platform?. Journal of Robotic Surgery, 2017, 11, 95-96.	1.8	4
35	Inguino-abdominal combined approach for laterally extended pelvic resection: a step by step procedure. International Journal of Gynecological Cancer, 2019, 29, 444-445.	2.5	2
36	Senhance robotic platform for ovarian borderline tumor treatment: minimally invasive robotic approach for conservative adnexal surgery. Gynecology and Pelvic Medicine, 0, 3, 27-27.	0.1	2

#	Article	IF	Citations
37	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan Journal of Clinical Oncology, 2019, 37, e17028-e17028.	1.6	1
38	Why Some Women Develop Cesarean Scar Defect (CSD)?., 2018,, 401-407.		0
39	Laparoscopic vs Transvaginal Cuff Closure After Total Laparoscopic Hysterectomy: A Randomized Trial by the Italian Society of Gynecologic Endoscopy. Obstetrical and Gynecological Survey, 2018, 73, 520-522.	0.4	O
40	51â€ln vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer. , 2019, , .		0
41	93â€Sacituzumab govitecan in uterine and ovarian carcinosarcomas. , 2019, , .		O
42	Percutaneous approach in early-stage ovarian cancer staging. Gynecology and Pelvic Medicine, 2020, 3, 29-29.	0.1	0
43	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma. , 2019, , .		0
44	Ovarian cyst enucleation with Senhance robotic platform. Asvide, 2020, 7, 225-225.	0.0	0
45	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma., 2019, , .		O